NEW YORK (GenomeWeb News) – UConn Health today announced a $3 million gift to advance research on genomics-guided cancer treatment at the integrated academic medical center.
The gift from Ray and Carole Neag will go toward the creation of the Neag Cancer Immunology Translational Research Program at the Neag Comprehensive Cancer Center to support clinical trials and other activities in cancer immunology based on original research at UConn Health.
Ray Neag graduated from the University of Connecticut in 1956 and was a co-founder of Arrow International, which provides catheter-based access and therapeutic products for critical and cardiac care. The company was acquired by medical technology firm Teleflex in 2007.
Pramod Srivastava will be the director of the Neag Cancer Immunology Translational Research Program. He is also the director of the Neag Comprehensive Cancer Center. The translational research program will launch a clinical trial later this year using DNA from patients to create personalized treatments for ovarian cancer, UConn said.